NO20003161D0 - Blandinger for nasal administrasjon av kannabinoider - Google Patents

Blandinger for nasal administrasjon av kannabinoider

Info

Publication number
NO20003161D0
NO20003161D0 NO20003161A NO20003161A NO20003161D0 NO 20003161 D0 NO20003161 D0 NO 20003161D0 NO 20003161 A NO20003161 A NO 20003161A NO 20003161 A NO20003161 A NO 20003161A NO 20003161 D0 NO20003161 D0 NO 20003161D0
Authority
NO
Norway
Prior art keywords
cannabinoids
compositions
nasal administration
nasal
administration
Prior art date
Application number
NO20003161A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003161L (no
Inventor
Peter Watts
Stanley Steward Davis
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Publication of NO20003161L publication Critical patent/NO20003161L/no
Publication of NO20003161D0 publication Critical patent/NO20003161D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20003161A 1997-12-19 2000-06-16 Blandinger for nasal administrasjon av kannabinoider NO20003161D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726916.1A GB9726916D0 (en) 1997-12-19 1997-12-19 Nasal formulation
PCT/GB1998/003703 WO1999032107A1 (en) 1997-12-19 1998-12-10 Compositions comprising cannabinoids

Publications (2)

Publication Number Publication Date
NO20003161L NO20003161L (no) 2000-06-16
NO20003161D0 true NO20003161D0 (no) 2000-06-16

Family

ID=10823941

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003161A NO20003161D0 (no) 1997-12-19 2000-06-16 Blandinger for nasal administrasjon av kannabinoider

Country Status (13)

Country Link
US (1) US6383513B1 (de)
EP (2) EP1437136B1 (de)
JP (1) JP2001526221A (de)
AR (1) AR017898A1 (de)
AT (1) ATE304351T1 (de)
AU (1) AU756669B2 (de)
CA (1) CA2313316A1 (de)
DE (1) DE69831620D1 (de)
GB (1) GB9726916D0 (de)
NO (1) NO20003161D0 (de)
NZ (1) NZ504679A (de)
WO (1) WO1999032107A1 (de)
ZA (1) ZA9811528B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US7648696B2 (en) 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
GB2361869B (en) * 2000-03-09 2004-09-22 Pharmasol Ltd Sublingual delivery of cannabis
ES2280343T3 (es) * 2000-03-09 2007-09-16 Gw Pharma Limited Composiciones farmaceuticas que contienen cannabis.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002231970B2 (en) * 2001-02-14 2007-08-16 CNX Therapeutics Limited Mucoadhesive pharmaceutical formulations
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
WO2002080883A2 (en) * 2001-03-27 2002-10-17 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
WO2003006010A1 (en) * 2001-07-10 2003-01-23 Norton Healthcare Limited Aerosol formulations of δ8 tetrahydrocannabinol
EP1321159A1 (de) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Betätigungsvorrichtung für Druckdosierinhalator mit lasergebohrten Löchern
EP1482917B1 (de) * 2002-02-01 2019-05-08 GW Pharma Limited Zusammensetzungen mit cannabidiolsäure zur behandlung von übelkeit, erbrechen, emesis, reisekrankheit oder ähnlichen zuständen
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
CA2474951A1 (en) * 2002-02-01 2003-08-07 Resolution Chemicals Limited Production of .delta.9 tetrahydrocannabinol
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
FI111733B (fi) * 2002-02-20 2003-09-15 Pedipharm Oy Uudet metyloidut syklodekstriinikompleksit
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
AR039194A1 (es) 2002-04-03 2005-02-09 Solvay Pharm Bv Formulacion de cannabinoides naturales estabilizados
PL209134B1 (pl) * 2002-04-03 2011-07-29 Solvay Pharm Bv Sposób wytwarzania kompozycji farmaceutycznej zawierającej naturalny związek kanabinoidowy i kompozycja farmaceutyczna otrzymywana tym sposobem
MXPA04011808A (es) * 2002-05-31 2005-09-12 Univ Mississippi Liberacion transmucosica de canabinoides.
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US20040228921A1 (en) * 2003-02-14 2004-11-18 Chowdhury Dipak K. Compositions and methods for delivery of therapeutic agents
WO2004092101A2 (en) * 2003-04-10 2004-10-28 Mallinckrodt Inc. Olivetol-cyclodextrin complexes and regio-selective process for preparing delta 9-tetrahydrocannabinol
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
AU2004235744A1 (en) * 2003-05-01 2004-11-18 Archimedes Development Limited Nasal administration of the LH-RH analog leuprolide
WO2005055945A2 (en) * 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
CN101005828B (zh) * 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
US20060078955A1 (en) * 2004-10-13 2006-04-13 Lin-Zhi International Method for retrieving delta9-THC from oral fluid
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
AU2005314021B2 (en) 2004-12-09 2010-02-11 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
ES2581212T3 (es) * 2005-11-07 2016-09-02 Murty Pharmaceuticals, Inc. Administración mejorada de tetahidrocannabinol
CN101415395B (zh) * 2006-03-29 2012-02-08 富士胶片株式会社 酪蛋白纳米粒子
EP2046290A4 (de) * 2006-08-04 2011-08-17 Insys Therapeutics Inc Wässrige dronabinolformulierungen
AU2007295178B2 (en) * 2006-09-15 2013-04-18 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
AU2015232994B2 (en) 2014-03-18 2020-05-28 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US20160143972A1 (en) * 2014-11-21 2016-05-26 Cannamark Inc. Method and apparatus for preparing a solid form of cannabinoid
CA2974292C (en) * 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
AU2016231788A1 (en) * 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CA2985332C (en) 2015-05-18 2023-01-03 5071, Inc. Homogenous cannabis compositions and methods of making the same
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
EP3380096A4 (de) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. Cannabisölzusammensetzungen und verfahren zur herstellung davon
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US10328216B2 (en) 2016-01-20 2019-06-25 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
EP3442521B1 (de) * 2016-04-15 2026-05-20 Sre Wellness Inc Mit cannabis infundierte süssstoffe und andere zusammensetzungen
CA3021095A1 (en) 2016-04-15 2017-10-19 Sre Wellness Inc. Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3478270A4 (de) * 2016-06-02 2019-11-27 Acerus Labs, Inc. Halbfeste und viskose flüssige nasale formulierungen von cannabinoiden
WO2018058235A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
CN110636834A (zh) * 2017-02-15 2019-12-31 分子浸剂有限公司 制剂
AU2018231789B2 (en) * 2017-03-09 2024-02-22 Izun Pharmaceuticals Corp. Stabilized protein-bound cannabinoid compositions
IL269305B2 (en) * 2017-03-16 2024-11-01 Izun Pharmaceuticals Corp Cannabinoid formulations and dosage
EP3644986A4 (de) * 2017-05-01 2021-01-06 MJ Wooly Corporation Methodologie und formulierung zur erzeugung von pulver einer verkapselten, cannabisbasierten komponente, die in einer polymermatrix eingebettet ist
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
US11273105B2 (en) 2017-06-16 2022-03-15 Sorse Technology Corporation Method for preparing solid forms of plant extract
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
WO2019014631A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
US20200345656A1 (en) 2017-11-29 2020-11-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
WO2019104442A1 (en) * 2017-11-30 2019-06-06 Canopy Growth Corporation Liquid dosage forms, methods of making and use
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2019135224A1 (en) * 2018-01-03 2019-07-11 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
CA3108214A1 (en) 2018-07-18 2020-01-23 Glatt Gmbh Extended release formulations of cannabinoids
US10383819B1 (en) 2018-07-23 2019-08-20 Callitas Therapeutics, Inc. Method to effect biphasic bioavailability of oral euphoric psychogenic cannabinoids
US20220008348A1 (en) * 2018-11-08 2022-01-13 Michael Golfetto Compound delivery systems and methods of production
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
EP3969143A4 (de) * 2019-05-13 2023-09-06 Buzzkill Labs, Inc. Prozesskartusche für tragbares medikamententestsystem
DE102019211195A1 (de) 2019-07-26 2021-01-28 Add Advanced Drug Delivery Technologies Ltd. Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats
WO2021046189A1 (en) 2019-09-06 2021-03-11 Quicksilver Scientific, Inc. Microemulsion delivery systems for water-based beverages
IL292377B2 (en) * 2019-10-21 2023-11-01 Esolate Ltd Thin compounds and their production
CN112891310A (zh) * 2019-12-03 2021-06-04 晨光生物科技集团股份有限公司 一种大麻二酚粉末的制备方法、制备得到的大麻二酚粉末及其用途
IL293476A (en) * 2019-12-05 2022-08-01 B G Negev Technologies And Applications Ltd At Ben Gurion Univ Biodegradable polymeric preparations, preparation methods and their uses
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US20230233635A1 (en) * 2020-05-26 2023-07-27 Rhodes Technologies Cannabinoid compositions and dosage forms for intranasal or inhalational delivery
EP3919046A1 (de) 2020-06-02 2021-12-08 Athenion AG Verfahren zur solubilisierung von natürlichen, endogenen und synthetischen cannabinoiden
WO2022011393A1 (en) 2020-07-08 2022-01-13 Shaman Naturals, Llc Compositions for preventing and treating diabetes
EP4181916A4 (de) * 2020-07-17 2024-12-18 Canna-Chemistries LLC Feste delta9-tetrahydrocannabinol (delta9-thc) zusammensetzungen
US20260069611A1 (en) 2024-09-06 2026-03-12 A2W Pharma Limited Stable cannabidiol oral formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DE3688617T2 (de) * 1986-11-03 1993-11-18 Allen W Jacobs Verfahren zur Beimischung einer festen teilchenförmigen Komponente in Aerosolpräparate zur Inhalation des Nikotins.
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
IL115245A (en) * 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
AU5806998A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US5989535A (en) * 1997-08-15 1999-11-23 Soma Technologies Polymeric bioadhesive emulsions and suspensions and methods of treatment

Also Published As

Publication number Publication date
GB9726916D0 (en) 1998-02-18
EP1039898A1 (de) 2000-10-04
ATE304351T1 (de) 2005-09-15
US6383513B1 (en) 2002-05-07
EP1437136A1 (de) 2004-07-14
JP2001526221A (ja) 2001-12-18
NO20003161L (no) 2000-06-16
ZA9811528B (en) 2000-10-12
NZ504679A (en) 2002-06-28
AR017898A1 (es) 2001-10-24
AU1497299A (en) 1999-07-12
WO1999032107A1 (en) 1999-07-01
DE69831620D1 (de) 2005-10-20
EP1437136B1 (de) 2005-09-14
AU756669B2 (en) 2003-01-23
CA2313316A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
NO20002851D0 (no) Blandinger for nasal administrasjon av medikamenter
DK0876131T3 (da) Sammensætninger til lægemiddelindgivelse til forbedret stabilitet af androgener
ATE304351T1 (de) Arzneizubereitungen enthaltend kannabinoide
FI972292A0 (fi) Administrering av diabetes
NO994757D0 (no) FramgangsmÕte for oral administrasjon av proteiner
IS5245A (is) Lyfjablanda úr ómeprasól
NO980126D0 (no) Plaster-formulering for perkantal administrering av fenantyl
HUP0104316A3 (en) Substituted benzopyran analogs for the treatment of inflammation and pharmaceutical compositions containing them
PT998272E (pt) Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
PT1066027E (pt) Composicao farmaceutica de topiramato
NO995113D0 (no) Substituerte benzopyranderivater for behandling av inflammasjon
NO985720L (no) Aerosol legemiddelformuleringer av formoterol
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
NO20040145L (no) Anvendelse av benzensulfonamidderivater for fremstilling av et medikament
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
FI955310L (fi) Farmaseuttinen koostumus flavonoidien antamiseksi oraalisesti
FI963679L (fi) Stabiloitu koostumus peptidien antamiseksi suun kautta
DK0973501T3 (da) Vandig suspension til nasal indgivelse af loteprednol
NO953367D0 (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
ID26137A (id) Komposisi farmasi baru dari uridin trifosfat
NO20012930D0 (no) Azatioprinsammensetninger for tykktarmsadministrering
FI970331L (fi) Lääkkeen antokoostumus virustenvastaisten aineiden nenään toteutettavaa antoa varten
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
FI973229L (fi) Uusi farmaseuttinen koostumus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application